Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Internet Pharmacy Hearing To Question FDA Progress In Curbing Illegal Sales

Executive Summary

The House Commerce/Oversight & Investigations Subcommittee will hold a hearing May 25 to examine FDA's progress in controlling illegal Internet drug sales in the 10 months since the agency last appeared before the subcommittee.

The House Commerce/Oversight & Investigations Subcommittee will hold a hearing May 25 to examine FDA's progress in controlling illegal Internet drug sales in the 10 months since the agency last appeared before the subcommittee.

In addition to FDA, the Department of Justice, U.S. Customs and possibly the National Association of Attorneys General are expected to testify.

Recent correspondence from Commerce Committee members indicates that they could be as critical of FDA's efforts as they were during a July 30, 1999 hearing (1 ).

A March 17 letter from Commerce Committee Chairman Bliley (R-Va.) states that since the hearing, "I have become increasingly troubled that the FDA is failing to fulfill its current regulatory obligations." The committee chairman also called FDA's drafting of a legislative proposal "to give itself even more responsibilities" in the Internet pharmacy arena "troubling." HHS unveiled its proposed legislation May 2 (2 (Also see "HHS Internet Pharmacy Certification Would Involve Existing Programs" - Pink Sheet, 8 May, 2000.)).

In a March 27 letter, Commerce Committee Ranking Member Dingell (D-Mich.) and Oversight & Investigations Subcommittee Ranking Member Klink (D-Penn.) indicate that they would like FDA to distinguish sales of pharmaceuticals from sales of other illegal products when discussing its Internet enforcement activities.

Henney's testimony for the March 21 Senate Health Committee hearing on Internet pharmacy "may have been inadvertently ambiguous," the letter says, citing her assertion that "36 arrests and 17 convictions have resulted from Office of Criminal Investigations investigations involving products being sold over the Internet" (3 ).

Given the context of the testimony, "one might assume that the 36 arrests and 17 convictions are directly related to activities involving online pharmacies," the letter states. However, in a March 23 response to an earlier letter, the agency said "FDA is not aware that any federal prosecutions or convictions for Internet violations have occurred at this time." The letter asks Henney for "help in reconciling these points."

Latest Headlines
See All
UsernamePublicRestriction

Register

PS036068

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel